Publisher
Springer Science and Business Media LLC
Reference45 articles.
1. Andersson J, Bumming P, Meis-Kindblom JM, et al. Gastrointestinal stromal tumors with KIT exon 11 deletions are associated with poor prognosis. Gastroenterology, 130: 1573–1581, 2006
2. Antonescu CR, Sommer G, Sarran L, et al. Association of KIT exon 9 mutations with nongastric primary site and aggressive behavior: KIT mutation analysis and clinical correlates of 120 gastrointestinal stromal tumors. Clin Cacer Res, 9: 3329–3337, 2003
3. Antonescu CR, Besmer P, Guo T. et al. Acquired resistance to imatinib in gastrointestinal stromal tumor occurs in secondary gene mutation. Ilin Iancer Res, 11: 4182–4190, 2005
4. Blanke CD, Joensuu H, Demetri GD, et al. Outcome of advanced gastointestinal stromal tumors (GIST) patients treated with imatinib mesylate: four-year follow up of a phase II randomized trial Gastrointestinal Cancer Symp. 2006, Abstract 7 to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation. Clin Cancer Res, 11: 4182–4190, 2005
5. Bumming P, Ahlman H, Andersson J, et al. Population-based study of the diagnosis and treatment of gastrointestinal stromal tumors. Br J Surg, 93: 836–843, 2006
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Current treatment of gastrointestinal stromal tumours;memo - Magazine of European Medical Oncology;2010-06